Completed PHASE2 INTERVENTIONAL 1-arm NCT02023593

FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

Phase Ⅱ Study of FOLFIRI as Second-Line Chemotherapy for Metastatic Esophageal Carcinoma

Sponsor: Yuhong Li

Conditions Advanced Esophageal Carcinoma

Interventions FOLFIRI

Updated 8 times since 2017 Last updated: Feb 14, 2023 Started: Mar 31, 2012 Primary completion: Dec 31, 2019 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced Esophageal Carcinoma and is currently completed. Yuhong Li leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2023 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Feb 2023 — Mar 2023 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Nov 2019 — Jan 2021 [monthly]

Recruiting PHASE2
Jun 2018 — Nov 2019 [monthly]

Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yuhong Li

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China